---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134733"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:14:52.291420+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports durable FVIII activity >16 mo in NHP hemophilia A study; MGX-001 IND on track for 2026

## Summary
- FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.
- MGX-001 bioengineered FVIII showed higher activity vs wild-type at similar integration rates in separate NHP study.
- No off-target editing identified to date in orthogonal assays; program targeting IND filing in 2026.
- Transient liver transaminase elevation at AAV/LNP dosing; no safety findings on albumin or bilirubin.

## SEC filing metadata
- accession: 0000950170-24-134733
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/0000950170-24-134733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/mgx-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134733
- JSON: https://secwatch.observer/filing/0000950170-24-134733.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.